Media Centre
Latest press releases
-
Vaxzevria is highly effective after one dose against severe disease or hospitalisation caused by Beta and Delta variants of concern
-
Acquisition of Alexion completed
-
Imfinzi approved in China for the treatment of extensive-stage small cell lung cancer
-
Status on FDA Advisory Committee vote on roxadustat in anaemia of chronic kidney disease
-
AstraZeneca receives final regulatory clearance for the proposed acquisition of Alexion from the UK’s Competition and Markets Authority
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800
Kim Blomley
Director Global Media Relations (Oncology)
+44 (0)1223 344 800
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Fiona Cookson
Director Global Media Relations (Covid-19)
+44 (0)1223 344 800
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
